Akero raised to Buy at Bank of America after liver drug data
Bank of America upgraded Akero Therapeutics (NASDAQ:AKRO) on Thursday, citing what it called “game-changing” data the company disclosed from a mid-stage trial for its lead drug efruxifermin against the liver disorder metabolic dysfunction-associated steatohepatitis (MASH).
Akero drug reverses liver scarring in study of severe MASH patients
Akero reported Monday strong results showing its drug efruxifermin reversed liver scarring in patients with cirrhosis caused by a disease known as MASH.
Akero's Efruxifermin Shows Cirrhosis Reversal In MASH Patients, Stock Soars In Pre-Market
In the trial, dubbed SYMMETRY, Efruxifermin demonstrated statistically significant cirrhosis reversal in patients with biopsy-confirmed compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis or MASH.
Akero soars as drug shows it reverses scarring in liver disease patients
By Sriparna Roy (Reuters) -Akero Therapeutics shares gained 106% before the bell on Monday, after its lead drug showed it can help patients with a type of liver disease to reverse scarring of the organ without worsening the condition in a keenly awaited mid-stage trial.
Akero Therapeutics Stock Doubles on Liver Disease Drug Trial Results
Akero Therapeutics shares traded near their all-time high as the drugmaker reported positive results in a study of its treatment for liver disease.
Akero: Reversal Of Cirrhosis With EFX Is A 'First' In F4 MASH Patients
Akero Therapeutics reports a 39% improvement in cirrhosis patients using EFX. See why AKRO stock is soaring with the breakthrough Phase 2b SYMMETRY data.
Akero Therapeutics: Promising SYMMETRY Trial Results Position Efruxifermin for Market Success
Jonathan Woo, an analyst from Phillip Securities, maintained the Buy rating on Akero Therapeutics (AKRO – Research Report). The associated ...
STAT10h
MASH drugs reach a meaningful tipping point for patients and investors
Akero's success in reversing cirrhosis follows that of Madrigal, making analysts and investors bullish on drugs to treat ...
biopharma-reporter2d
Akero Therapeutics succeeds with MASH liver treatment at phase 2
Akero Therapeutics announced statistically significant results from a Phase 2b trial of efruxifermin this week, a fibroblast ...
BioSpace3d
Akero Rebounds as Benefit Deepens in Key Mid-Stage MASH Trial
After missing the primary endpoint in the Phase IIb SYMMETRY trial, Akero Therapeutics’ lead molecule, efruxifermin, showed ...
FierceBiotech3d
Akero's stock doubles as midphase MASH trial generates 'transformational' data: analyst
Akero Therapeutics has hit a home run, reporting statistically significant results in two key 96-week metabolic ...
Liver Disease-Focused Akero Therapeutics Stock Soars Over 100% On Monday - Here's Why
Akero Therapeutics, Inc. (NASDAQ:AKRO) released preliminary topline week 96 results from SYMMETRY Phase 2b study evaluating ...
Why did Akero (AKRO) stock soar 110% on Monday?
Akero Therapeutics Inc (NASDAQ: AKRO) says its candidate treatment for a serious liver disease demonstrated exceptional ...
Hosted on MSN2d
Akero Shares Skyrocket as MASH Drug Delivers Game-Changing Results
Shares of Akero Therapeutics ($AKRO) skyrocketed on Monday following game-changing results from its lead drug, efruxifermin, ...
Akero Therapeutics Shares Surge 106% as Phase 2b Study Shows Significant Cirrhosis Reversal
On Monday, at 10:23 a.m. GMT-5, Akero Therapeutics ( AKRO, Financials) saw its stock soar by 106.63%, closing at $54.10, ...